Cargando…
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
BACKGROUND: There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1). METHODS: Through a literature-based approach, we discuss mechanisms of resist...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995165/ https://www.ncbi.nlm.nih.gov/pubmed/32005279 http://dx.doi.org/10.1186/s13058-020-1252-7 |